CSF1R inhibitionitors have been developed as a potential route to reduce the presence of TAMs in the tumor microenvironment. As of 2017, CSF1R inhibitionitors that are currently in early stage clinical trials include Pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, Emactuzumab, AMG820, IMC-CS4, MCS110, and Cabiralizumab.
Alpha Lifetech is proud to offer biosimilar antibodies product, Cabiralizumab Biosimilar, designed to revolutionize the treatment of various research conditions. Our Cabiralizumab Biosimilar antibody product is manufactured using biotechnological processes, ensuring high purity, potency, and consistency in every batch. Alpha Lifetech adheres to stringent quality control measures throughout the production process, guaranteeing the safety and efficacy of our biosimilar antibody product. Choose Alpha Lifetech’s biosimilar antibody product for a reliable, effective, and cost-efficient treatment.